MA30358B1 - Quinazolines pour l'inhibition de pdk1 - Google Patents

Quinazolines pour l'inhibition de pdk1

Info

Publication number
MA30358B1
MA30358B1 MA31336A MA31336A MA30358B1 MA 30358 B1 MA30358 B1 MA 30358B1 MA 31336 A MA31336 A MA 31336A MA 31336 A MA31336 A MA 31336A MA 30358 B1 MA30358 B1 MA 30358B1
Authority
MA
Morocco
Prior art keywords
pdk1
quinazolines
inhibition
compounds
relates
Prior art date
Application number
MA31336A
Other languages
English (en)
Inventor
Savithri Ramurthy
Xiaodong Lin
Sharadha Subramanian
Alice C Rico
Xiaojing M Wang
Rama Jain
Jeremy M Murray
Steven E Basham
Robert L Warne
Wei Shu
Yasheen Zhou
Mina Aikawa
Payman Amiri
Johanna M Jansen
Keith B Pfister
Simon C Ng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30358B1 publication Critical patent/MA30358B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne de nouveaux composés qui sont des inhibiteurs de PDK1. Elle concerne également des compositions pharmaceutiques contenant ces composés, et des méthodes utilisant ces composés et compositions pour le traitement de maladies à évolution chronique comme le cancer
MA31336A 2006-04-06 2008-10-27 Quinazolines pour l'inhibition de pdk1 MA30358B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79030406P 2006-04-06 2006-04-06

Publications (1)

Publication Number Publication Date
MA30358B1 true MA30358B1 (fr) 2009-04-01

Family

ID=38476139

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31336A MA30358B1 (fr) 2006-04-06 2008-10-27 Quinazolines pour l'inhibition de pdk1

Country Status (22)

Country Link
US (1) US7932262B2 (fr)
EP (1) EP2004615A2 (fr)
JP (1) JP2009532486A (fr)
KR (1) KR20080111114A (fr)
CN (1) CN101454294A (fr)
AR (1) AR060358A1 (fr)
AU (1) AU2007235339A1 (fr)
BR (1) BRPI0710521A2 (fr)
CA (1) CA2648529A1 (fr)
CR (1) CR10427A (fr)
EA (1) EA200870415A1 (fr)
EC (1) ECSP088823A (fr)
GT (1) GT200800202A (fr)
MA (1) MA30358B1 (fr)
MX (1) MX2008012852A (fr)
NO (1) NO20084665L (fr)
PE (1) PE20080059A1 (fr)
SM (1) SMP200800059B (fr)
TN (1) TNSN08375A1 (fr)
TW (1) TW200808739A (fr)
WO (1) WO2007117607A2 (fr)
ZA (1) ZA200808307B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673003A1 (fr) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines destines a l'inhibition de pdk1
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
WO2009084695A1 (fr) 2007-12-28 2009-07-09 Carna Biosciences Inc. Dérivé de 2-aminoquinazoline
ATE535515T1 (de) * 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
US20100121052A1 (en) * 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
CA2748319A1 (fr) * 2008-12-29 2010-07-08 Fovea Pharmaceuticals Composes quinazoline substitues de formule generale (i) et leurs utilisations pour le traitement de troubles relatifs au dereglement entraine par une tyrosine kinase
WO2012044090A2 (fr) * 2010-09-29 2012-04-05 크리스탈지노믹스(주) Nouveau composé d'aminoquinazoline possédant une action inhibitrice de la protéine kinase
WO2013050527A1 (fr) 2011-10-05 2013-04-11 H. Lundbeck A/S Dérivés de quinazoline en tant qu'inhibiteurs de l'enzyme pde10a
KR101360948B1 (ko) * 2012-01-17 2014-02-12 한국과학기술연구원 신규한 2-아미노퀴나졸린 유도체 및 이를 유효성분으로 포함하는 항암제
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
ES3069593T3 (en) * 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
EP3078660B1 (fr) * 2013-12-06 2022-07-13 MycHunter Therapeutics, Inc. Nouveau dérivé quinazoline
US9815797B2 (en) * 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
JP6225358B2 (ja) 2014-09-01 2017-11-08 日本曹達株式会社 ２−アミノ置換ベンズアルデヒド化合物を製造する方法
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
CA2972014C (fr) 2014-12-24 2019-09-24 Gilead Sciences, Inc. Composes de pyrimidine fusionnes pour le traitement du vih
SG11201705184PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
EP3270694A4 (fr) * 2015-02-17 2018-09-05 Neupharma, Inc. Entités chimiques, compositions et méthodes particulières
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017005137A1 (fr) * 2015-07-03 2017-01-12 吉林大学 Composé de quinazoline, intermédiaire associé, son procédé de préparation, composition pharmaceutique et utilisations associées
US10494378B2 (en) * 2015-07-21 2019-12-03 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
ES2967344T3 (es) 2015-10-02 2024-04-29 Sentinel Oncology Ltd Derivados de 2-aminoquinazolina como inhibidores de cinasa p70s6
CN105753793B (zh) * 2016-01-19 2018-09-04 河北医科大学 芳甲酰脲偶联喹唑啉类化合物及其制备方法、药物组合物及药物用途
CN109843858B (zh) 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
RU2761824C2 (ru) * 2018-08-03 2021-12-13 Закрытое Акционерное Общество "Биокад" Ингибиторы CDK8/19
CN110872243B (zh) * 2018-08-31 2023-03-31 四川科伦博泰生物医药股份有限公司 磺酰胺类化合物、其制备方法及用途
CN109320511A (zh) * 2018-10-26 2019-02-12 广安凯特制药有限公司 一种高纯度帕博西尼中间体产品及其制备方法
JP2022535086A (ja) * 2019-06-05 2022-08-04 アドバンスド テクノロジーズ フォー ノベル セラピューティクス，エルエルシー 修飾ペプチドおよび関連する使用方法
EP4090663A1 (fr) * 2020-01-15 2022-11-23 Blueprint Medicines Corporation Inhibiteurs de map4k1
WO2021180032A1 (fr) * 2020-03-13 2021-09-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Nouveaux procédés thérapeutiques
CN114315798B (zh) * 2020-09-29 2025-03-25 安思科(苏州)医药科技有限公司 喹唑啉类化合物及其药物组合物
EP4240361A4 (fr) * 2020-11-09 2024-09-25 Merck Sharp & Dohme LLC Inhibiteurs, du type 2-aminoquinazoline à substitution 7-azole, de hpk1
EP4240363A4 (fr) * 2020-11-09 2024-10-23 Merck Sharp & Dohme LLC 2-aminoquinazoline 7-phényl substituée, inhibiteurs de hpk1
JP2024511012A (ja) * 2021-03-24 2024-03-12 アトス セラピューティクス，インコーポレイテッド キナーゼ関連疾患の処置のための小分子
WO2022222951A1 (fr) * 2021-04-22 2022-10-27 浙江海正药业股份有限公司 Dérivé cyclique condensé aromatique, son procédé de préparation et son utilisation
CN115583946B (zh) * 2021-07-06 2026-01-16 赛诺哈勃药业（成都）有限公司 杂环化合物及其作为cdk抑制剂的用途
CN113999206B (zh) * 2021-12-31 2022-04-12 北京鑫开元医药科技有限公司 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用
CN114533733A (zh) * 2021-12-31 2022-05-27 北京鑫开元医药科技有限公司 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法
WO2023138412A1 (fr) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Composés de pyrimidin-2-amine fusionnés utilisés en tant qu'inhibiteurs de cdk20
WO2023143135A1 (fr) * 2022-01-28 2023-08-03 赛诺哈勃药业（成都）有限公司 Dérivé de quinazoline et son utilisation
CN116672450A (zh) * 2022-02-23 2023-09-01 智宠制药（北京）有限公司 Hpk1抑制剂在治疗干扰素相关疾病中的应用
WO2023218241A1 (fr) * 2022-05-13 2023-11-16 Voronoi Inc. Composés dérivés d'hétéroaryle et composition pharmaceutique les comprenant
WO2024020380A1 (fr) * 2022-07-18 2024-01-25 Iambic Therapeutics, Inc. Composés de quinazoline et procédés d'utilisation
WO2024131938A1 (fr) * 2022-12-23 2024-06-27 赛诺哈勃药业（成都）有限公司 Composé de quinazoline et son utilisation
WO2024186579A1 (fr) * 2023-03-03 2024-09-12 Deliver Therapeutics, Inc. Inhibiteurs de protéine kinase et leurs utilisations
KR20250027005A (ko) 2023-08-18 2025-02-25 인하대학교 산학협력단 Itgb4 억제 활성을 나타내는 화합물을 유효성분으로 포함하는 심혈관계 질환 예방 또는 치료용 약학 조성물
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2025155742A1 (fr) * 2024-01-17 2025-07-24 Iambic Therapeutics, Inc. Procédés d'utilisation de composés de quinazoline
WO2026008750A1 (fr) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Nouveaux composés carboxamides
WO2026050773A1 (fr) * 2024-09-02 2026-03-05 Deliver Therapeutics, Inc. Inhibiteurs de protéine kinase et leurs utilisations
WO2026119962A1 (fr) 2024-12-04 2026-06-11 Syngenta Crop Protection Ag Nouveaux composés phényl carboxamide

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73044A (en) 1868-01-07 John c
US171303A (en) 1875-12-21 Improvement in corn-stalk knives
US134846A (en) 1873-01-14 Half his eight to william h
JPS6041077B2 (ja) * 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) * 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
WO1988007045A1 (fr) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
EP0383919A4 (en) 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0540185A1 (fr) 1991-10-10 1993-05-05 Schering Corporation Dérivés de staurosporine-N-oxide N-substitués
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
DE69331228T4 (de) 1992-09-21 2002-09-05 Kyowa Hakko Kogyo Co., Ltd. Heilmittel für thrombozytopenia
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DK0708772T3 (da) * 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
EP1449529B1 (fr) 1993-12-23 2010-01-27 Eli Lilly And Company Inhibiteurs de la protéine-kinase c
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (fr) 1995-08-11 1997-02-27 Yale University Synthese d'indolocarbazols glycosyles
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
DE69635966T2 (de) 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
KR100447918B1 (ko) * 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
CN1189562C (zh) 1996-08-02 2005-02-16 吉倪塞思技术公司 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
EP1017394B1 (fr) 1997-07-12 2005-12-07 Cancer Research Technology Limited Derives de purine inhibant la kinase dependant de la cycline
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
AU6014900A (en) 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
CA2386955A1 (fr) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
US6982260B1 (en) * 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
EP1274718B1 (fr) 2000-04-12 2006-10-18 Genaera Corporation Procede de preparation de 7.alpha.-hydroxy 3-aminosubstitues sterols au moyen de produits intermediaires dotes d'un groupe 7.alpha.-hydroxy non protege
CA2413134C (fr) 2000-06-30 2010-05-11 Glaxo Group Limited Composes ditosylates de quinazoline
BRPI0113757B8 (pt) * 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
EP1404689A1 (fr) 2001-07-02 2004-04-07 Debiopharm S.A. Substance active a base d'oxaliplatine presentant une faible teneur en acide oxalique
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
MXPA04009541A (es) 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US6900342B2 (en) * 2002-05-10 2005-05-31 Dabur India Limited Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CA2511646A1 (fr) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones antiviraux et immunostimulants
EP1590341B1 (fr) 2003-01-17 2009-06-17 Warner-Lambert Company LLC Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire
WO2004064759A2 (fr) 2003-01-21 2004-08-05 Chiron Corporation Utilisation de composes de tryptanthrine dans la potentialisation immunologique
WO2004087153A2 (fr) 2003-03-28 2004-10-14 Chiron Corporation Utilisation de petites molecules de composes pour une immunopotentialisation
WO2005030776A1 (fr) 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Derives de pyrazolopyrrole utilises en tant qu'inhibiteurs de proteines kinases
AU2005284835A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
EP1878727A4 (fr) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd Dérivés de 2-aminoquinazoline
WO2006137421A1 (fr) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent pour administration topique
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use

Also Published As

Publication number Publication date
BRPI0710521A2 (pt) 2012-03-13
US7932262B2 (en) 2011-04-26
PE20080059A1 (es) 2008-03-05
AU2007235339A8 (en) 2008-11-20
SMAP200800059A (it) 2008-11-12
ECSP088823A (es) 2008-12-30
GT200800202A (es) 2009-06-25
MX2008012852A (es) 2008-11-28
CN101454294A (zh) 2009-06-10
WO2007117607A2 (fr) 2007-10-18
CA2648529A1 (fr) 2007-10-18
TNSN08375A1 (en) 2009-12-29
JP2009532486A (ja) 2009-09-10
ZA200808307B (en) 2010-01-27
AU2007235339A1 (en) 2007-10-18
EA200870415A1 (ru) 2009-02-27
WO2007117607A3 (fr) 2007-12-21
KR20080111114A (ko) 2008-12-22
AR060358A1 (es) 2008-06-11
NO20084665L (no) 2009-01-06
TW200808739A (en) 2008-02-16
WO2007117607A9 (fr) 2008-03-06
SMP200800059B (it) 2009-09-07
CR10427A (es) 2009-01-27
US20100048561A1 (en) 2010-02-25
EP2004615A2 (fr) 2008-12-24

Similar Documents

Publication Publication Date Title
MA31001B1 (fr) Quinazolines destines a l&#39;inhibition de pdk
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
DE602004013563D1 (de) Rantagonisten
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d&#39;alzheimer
EP1606286A4 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MA31167B1 (fr) Inhibiteurs de l&#39;activite de akt
MA30526B1 (fr) Inhibiteurs de prolyle hydroxylase
MA32393B1 (fr) Composés et compositions servant d&#39;inhibiteurs de kinases
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
WO2007087151A3 (fr) Méthode de traitement d&#39;un dysfonctionnement cognitif